Elevated levels of Aβ42 and phosphorylated tau (P‐T181‐tau and P‐S396‐tau) in plasma NDEVs were observed in patients with AD even before symptom onset, and could predict AD conversion from mild cognitive impairment (MCI).10, 11. This evidence concerns the gene MAPT and Alzheimer disease.